Elutia Inc. Share Price & Technical Analysis
ELUT · $1.16 (-3.33%)
Healthcare / Medical Devices
$1.16
-3.33%
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
20% return in May, -1% avg return in past 3 year May month.
46% return in 2026, -7% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 43% | 0% | -17% | 0% | 20% | – | – | – | – | – | – | – | 46% |
| 25 | -16% | 14% | -24% | -12% | -22% | 11% | 0% | 21% | -61% | 0% | -33% | 17% | -105% |
| 24 | 64% | -3% | -11% | -10% | 14% | 52% | -26% | 8% | -5% | -16% | 24% | -10% | 82% |
| 23 | 7% | -11% | -65% | 33% | 5% | 20% | -4% | -29% | -7% | -20% | 50% | 22% | 2% |
| 22 | 3% | 27% | -18% | 15% | -9% | 27% | 2% | 11% | -1% | 17% | -12% | -2% | 59% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Downtrend · Uptrend
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$48.89M
P/E ratio
—
52W high
$2.64
52W low
$0.50
Volume
3,07,584
Beta
0.76
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Elutia Inc. share price today?
- Elutia Inc. (ELUT) last traded around $1.16 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ELUT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ELUT. Download the app for real-time alerts.
- How can I analyze Elutia Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.